DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.
Gupta A. et al, (2014), Ann Oncol, 25, 968 - 974
The utility of restaging PET-CT In predicting progression to unresectable oesophageal cancer after neoadjuvant chemotherapy
Findlay JM. et al, (2014), BRITISH JOURNAL OF SURGERY, 101, 19 - 19
Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma.
Sinha R. et al, (2014), Br J Dermatol, 170, 997 - 999
XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: Suitability as a biomarker for patient selection
Hatch SB. et al, (2014), International Journal of Cancer, 134, 1495 - 1503
XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: suitability as a biomarker for patient selection.
Hatch SB. et al, (2014), Int J Cancer, 134, 1495 - 1503
A STUDY OF THE EFFECT OF DABRAFENIB (D) AS AN INDUCER OF CYTOCHROME P450 (CYP) USING WARFARIN (W) AS A PROBE.
Carson SW. et al, (2014), CLINICAL PHARMACOLOGY & THERAPEUTICS, 95, S36 - S36
A STUDY OF THE EFFECTS OF INHIBITION OF CYP3A4 BY KETOCONAZOLE (K) AND CYP2C8 BY GEMFIBROZIL (G) ON THE PHARMACOKINETICS DABRAFENIB (D)
Suttle B. et al, (2014), CLINICAL PHARMACOLOGY & THERAPEUTICS, 95, S89 - S90
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.
Valle JW. et al, (2014), J Clin Oncol, 32, 504 - 512
Discovery of prognostic and predictive tissue biomarkers in patients with resectable esophageal cancer
MacGregor TP. et al, (2014), JOURNAL OF CLINICAL ONCOLOGY, 32
Phase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence.
Payne MJ. et al, (2014), J Clin Oncol, 32, 185 - 190
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): Preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study
Corrie PG. et al, (2014), The Lancet Oncology, 15, 620 - 630
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.
Greenhalf W. et al, (2014), J Natl Cancer Inst, 106
Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study.
Lorigan P. et al, (2014), Br J Dermatol, 170, 87 - 95
A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours.
Horsley L. et al, (2013), Cancer Chemother Pharmacol, 72, 1343 - 1352
A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours
Horsley L. et al, (2013), Cancer Chemotherapy and Pharmacology, 72, 1343 - 1352
Pharmacokinetics of orally administered rucaparib in patients with advanced solid tumors.
Shapiro G. et al, (2013), MOLECULAR CANCER THERAPEUTICS, 12
A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors.
New M. et al, (2013), Cell Death Differ, 20, 1306 - 1316
DNA repair proteins XPF and MUS81 are predictive biomarkers for neoadjuvant oxaliplatin-fluorouracil chemotherapy in patients with operable oesophageal adenocarcinoma
MacGregor T. et al, (2013), BRITISH JOURNAL OF SURGERY, 100, 56 - 56
Results of restaging oesophageal and junctional cancer after neoadjuvant chemotherapy with PET-CT alone
Findlay J. et al, (2013), BRITISH JOURNAL OF SURGERY, 100, 46 - 46
Routine staging endoscopic ultrasound is not required for T2-T4a oesophageal/junctional cancer
Findlay J. et al, (2013), BRITISH JOURNAL OF SURGERY, 100, 45 - 45